Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:CELZ NASDAQ:QLGN NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$0.62+1.5%$0.66$0.59▼$3.12$2.18M1.01202,399 shs112,883 shsCELZCreative Medical Technology$3.23+0.9%$3.23$1.69▼$6.90$8.33M2.0630,269 shs42,784 shsQLGNQualigen Therapeutics$5.23-6.4%$2.63$1.61▼$10.45$8.89M0.324.81 million shs265,031 shsTNFATNF Pharmaceuticals$5.75+12.7%$7.02$3.24▼$195.00$10.62M2.043.51 million shs8.14 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-1.62%-5.53%-39.71%-68.78%CELZCreative Medical Technology0.00%-2.42%-2.42%+21.89%+7.67%QLGNQualigen Therapeutics0.00%+3.36%+209.47%+54.28%-36.80%TNFATNF Pharmaceuticals0.00%+23.92%+74.24%-49.20%-96.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$0.62+1.5%$0.66$0.59▼$3.12$2.18M1.01202,399 shs112,883 shsCELZCreative Medical Technology$3.23+0.9%$3.23$1.69▼$6.90$8.33M2.0630,269 shs42,784 shsQLGNQualigen Therapeutics$5.23-6.4%$2.63$1.61▼$10.45$8.89M0.324.81 million shs265,031 shsTNFATNF Pharmaceuticals$5.75+12.7%$7.02$3.24▼$195.00$10.62M2.043.51 million shs8.14 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-1.62%-5.53%-39.71%-68.78%CELZCreative Medical Technology0.00%-2.42%-2.42%+21.89%+7.67%QLGNQualigen Therapeutics0.00%+3.36%+209.47%+54.28%-36.80%TNFATNF Pharmaceuticals0.00%+23.92%+74.24%-49.20%-96.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.00Buy$14.502,257.72% UpsideCELZCreative Medical Technology 1.50ReduceN/AN/AQLGNQualigen Therapeutics 1.00SellN/AN/ATNFATNF Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CANF, QLGN, TNFA, and CELZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025CELZCreative Medical TechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025QLGNQualigen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TNFATNF PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/16/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/2/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/12/2025CELZCreative Medical TechnologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$560K3.89N/AN/A$1.76 per share0.35CELZCreative Medical Technology$10K833.34N/AN/A$3.63 per share0.89QLGNQualigen Therapeutics$4.98M1.79N/AN/A($4.12) per share-1.27TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACELZCreative Medical Technology-$5.49M-$3.18N/AN/AN/AN/A-82.99%-79.49%11/14/2025 (Estimated)QLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/13/2025 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$231.00N/A∞N/AN/A-69.21%-33.98%11/13/2025 (Estimated)Latest CANF, QLGN, TNFA, and CELZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025TNFATNF PharmaceuticalsN/A-$18.00N/A-$0.18N/AN/A8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A8/8/2025Q2 2025CELZCreative Medical Technology-$0.63-$0.48+$0.15-$0.48N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACELZCreative Medical TechnologyN/A23.8623.86QLGNQualigen TherapeuticsN/A0.710.71TNFATNF PharmaceuticalsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CELZCreative Medical Technology1.42%QLGNQualigen Therapeutics3.18%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CELZCreative Medical Technology1.80%QLGNQualigen Therapeutics1.80%TNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCELZCreative Medical Technology52.58 million2.53 millionNot OptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/ACANF, QLGN, TNFA, and CELZ HeadlinesRecent News About These CompaniesQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"September 26, 2025 | tmcnet.comTNF Pharmaceuticals changes name to Q/C TechnologiesSeptember 25, 2025 | msn.comTNF Pharmaceuticals stock soars after strategic pivot to quantum computingSeptember 25, 2025 | investing.comTNF Pharmaceuticals regains compliance with NasdaqSeptember 17, 2025 | msn.comTNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 17, 2025 | businesswire.comTNF Pharmaceuticals Announces Closing of $7 Million Private PlacementSeptember 4, 2025 | businesswire.comTNF Pharmaceuticals stock climbs after securing exclusive crypto computing rightsSeptember 2, 2025 | investing.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comTNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceAugust 29, 2025 | finance.yahoo.comTNF Pharmaceuticals announces improved financial positionAugust 20, 2025 | msn.comTNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationAugust 19, 2025 | businesswire.comTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMAkers files written objection to her Judicial Investigative admonishmentJuly 4, 2025 | wvgazettemail.comWDorothy Marillyn AkersJuly 2, 2025 | chattanoogan.comCNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comTNF Pharmaceuticals, Inc. (TNFA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAdmonishing Akers, Sweeney Wrong; Will Make Matters WorseJune 26, 2025 | wvmetronews.comWTNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory DiseaseJune 25, 2025 | finance.yahoo.comClinton native Cam Akers signs with New Orleans SaintsJune 17, 2025 | msn.comSaints' Cam Akers: Gets chance with SaintsJune 15, 2025 | cbssports.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, QLGN, TNFA, and CELZ Company DescriptionsCan-Fite BioPharma NYSE:CANF$0.62 +0.01 (+1.50%) Closing price 10/3/2025 03:57 PM EasternExtended Trading$0.61 0.00 (-0.65%) As of 10/3/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Creative Medical Technology NASDAQ:CELZ$3.23 +0.03 (+0.94%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$3.15 -0.08 (-2.45%) As of 10/3/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Qualigen Therapeutics NASDAQ:QLGN$5.23 -0.36 (-6.44%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.20 -0.04 (-0.67%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.TNF Pharmaceuticals NASDAQ:TNFA$5.75 +0.65 (+12.75%) As of 10/3/2025TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
